ClinicalTrials.gg
Not yet recruitingNCT06970756Updated May 18, 2025

A Phase I Clinical Study to Evaluate the Safety of PCV26 in Individuals ≥60

A Phase 1 interventional study of 26-valent Pneumococcal Conjugate Vaccine and 13-valent Pneumococcal Conjugate Vaccine in Pneumococcal Diseases, sponsored by Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. Not yet recruiting at 1 site in Australia. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-18.

Sponsored by Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (part of Chongqing Zhifei Biological Products Co., Ltd.) · Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Pneumococcal Infections with a site in Australia — 3 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal Infections · Australia.

Planned enrollment
14th of 16
60 · median 851
Started
2025
with 1 other
Phase 1
3 of 16
2 open now
Registered
14th of 16
by date
Lead sponsor
1 of 16
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Among the 16 studies in Pneumococcal Infections with a site in Australia, this one is the 14th largest by planned enrollment, is one of 2 that started in 2025, is one of 3 in phase 1, and was the 14th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

3 of the 16 studies in Pneumococcal Infections with a site in Australia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Pneumococcal Infections with a site in Australia, or all of them as a file.
02

Study summary

This Phase I, randomized, double-blind, parallel-controlled study is to be conducted in healthy adults aged 60 and above. Participants will be randomly assigned in a 1:1 ratio to receive either 26-valent Pneumococcal Conjugate Vaccine (PCV26) or the comparator (PCV13) on Day 1 (Visit 1). Solicited adverse events (AEs) will be collected for 7 days post-vaccination and unsolicited AEs for 28 days post-vaccination, with safety data limited to serious adverse events (SAEs), and newly diagnosed chronic medical conditions (NDCMCs) collected up to 6 months post-vaccination.

03

Conditions studied

  • Pneumococcal Diseases

Keywords

  • 26-valent Pneumococcal Conjugate Vaccine
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 60 years or older at the time of enrollment.
  • Evidence of a personally signed and dated ICF indicating that the participant has been informed of all pertinent aspects of the study.
  • Able to comply with the protocol, and capable of using a thermometer, a ruler, and fill out the diary card and contact card as required.
  • Negative pregnancy test (urine) for female participants of . Male and non-pregnant, non-lactating females must also meet one of the following criteria: a). Female participant of nonchildbearing potential; male participant not able to father children; b). Agrees to consistently practice until at least 28 days after vaccination by one of the following methods: condoms, male or female, with or without spermicide; diaphragm or cervical cap with spermicide; intrauterine device; contraceptive pills or patch; Norplant, Depo-Provera, or other FDA approved contraceptive method; or a female participant with a male partner who has previously undergone a vasectomy.

Exclusion criteria

Exclusion Criteria:

  • Current febrile illness (oral temperature ≥100.4°F [≥38.0°C]) within 48 hours before vaccine administration.
  • History of an infectious disease caused by Streptococcus pneumoniae confirmed by any modality of diagnosis within the last 3 years.
  • History of any pneumococcal vaccination within the last 3 years.
  • History of severe allergic reactions to any drug or vaccine, especially to any component of pneumococcal vaccines (including Pneumovax, any other tetanus toxoid-containing vaccine, or 13-valent pneumococcal conjugate vaccine), such as respiratory distress, angioedema, anaphylactic shock, allergic purpura, or thrombocytopenic purpura.
  • History of any serious chronic disorder including respiratory diseases (eg., severe requiring supplemental oxygen, severe asthma), chronic hepatitis, chronic kidney disease (eg., end-stage renal disease with or without dialysis), clinically unstable cardiac diseases or cardiovascular diseases (eg., untreated or resistant hypertension [repeated office SBP >150 mmHg and/or DBP >95 mmHg], chronic cardiac insufficiency, coronary atherosclerotic heart disease), or forms of drug or alcohol abuse or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study.
  • Participants with known or suspected immunodeficiency or other conditions associated with , including, but not limited to, immunoglobulin class/subclass deficiencies, generalized , (HIV) infection, leukemia, lymphoma, or organ or bone marrow transplant.
  • History of thrombocytopenia, any coagulation disorder, receiving anticoagulant therapy, or any condition contraindicating administration of intramuscular injections.
  • History of asplenia, splenectomy, or functional asplenia for any reason.
  • Participants who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic , or planned receipt within 28 days of vaccination. If systemic corticosteroids have been administered short term (\<14 days) for treatment of an acute illness, participants should not be enrolled into the study until corticosteroid therapy has been discontinued for at least 28 days before vaccination. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
  • Participants who has an acute illness or exacerbation of chronic illness ≤3 days before enrollment, or use of antipyretics, analgesics, and antihistamines (eg, acetaminophen, ibuprofen, aspirin) within this timeframe.
  • Participants who have received any non- ≤7 days before receipt of study vaccine; is scheduled to receive any non-live vaccine within 7 days (≤7 days) following receipt of the study vaccine; has received any live vaccine ≤14 days before receipt of the study vaccine; or is scheduled to receive any live vaccine within 7 days (≤7 days) following receipt of the study vaccine.
  • Participation in other studies involving study drug(s), study vaccines, or study devices within 28 days prior to study enrollment and/or during study participation. Participation in purely observational studies is acceptable.
  • Any ≥ Grade 2 laboratory abnormality or any lab abnormality that, in the opinion of the investigator, renders the participant unsuitable for enrollment.
  • Planning to relocate before the end of the study or planning to be away from the local area for an extended period during the scheduled study visits.
  • Any condition that, in the opinion of the investigator, may interfere with the assessment of the study objectives.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Vaccine group

    30 subjects aged ≥60 are enrolled in this group.

    Biological: 26-valent Pneumococcal Conjugate Vaccine

  • Active comparator
    Active control group

    30 subjects aged ≥ 60 years are enrolled in this group.

    Biological: 13-valent Pneumococcal Conjugate Vaccine

Interventions

  • Biological26-valent Pneumococcal Conjugate Vaccine

    Subjects were treated with a single intramuscular injection of 26-valent Pneumococcal Conjugate Vaccine.

  • Biological13-valent pneumococcal vaccineStudies of 13-valent pneumococcal vaccine13-valent pneumococcal vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects were treated with a single intramuscular injection of 13-valent Pneumococcal Conjugate Vaccine.

06

What researchers measure

Primary outcomes

  1. Solicited AEs within 0-7 days after vaccination

    The frequencies and percentages of participants reporting solicited AEs in injection within 7 days after vaccination in each group

    Time frame: Within 0-7 days after vaccination.

  2. Solicited systemic AEs within 0-7 days after vaccination

    The frequencies and percentages of participants reporting solicited systemic AEs within 7 days after vaccination in each group.

    Time frame: Within 0-7 days after vaccination.

Secondary outcomes

  1. Unsolicited AEs within 0-28 days after vaccination

    The frequencies and percentages of participants reporting unsolicited AEs within 0-28 days after vaccination in each group.

    Time frame: Within 0-28 days after vaccination.

  2. SAEs and newly diagnosed chronic medical conditions (NDCMCs) within 6 months after vaccination

    The frequencies and percentages of participants reporting SAEs and NDCMCs within 6 months after vaccination.

    Time frame: Within 0-6 months after vaccination.

  3. Laboratory testing clinically abnormalities on the 7th day after vaccination

    The frequencies and percentages of participants with laboratory testing clinically abnormalities on the 7th day after vaccination in each group.

    Time frame: On the 7th day after vaccination

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for Nov 2025, 6 months later.

Of 27 phase 1 interventional studies under Pneumococcal Infections, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2025
First posted
May 14, 2025
StartEst.
May 27, 2025
Primary completionEst.
Nov 27, 2025
CompletionEst.
Jul 10, 2026
Last update
May 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06970756
Responsible party
Sponsor
First posted
May 14, 2025
Start date
May 27, 2025 (estimated)
Primary completion
Nov 27, 2025 (estimated)
Completion
Jul 10, 2026 (estimated)
Last update
May 18, 2025

Study contacts

Wenjian Fang
Contact
fangwenjian@zhifeishengwu.com
+86-18611630252
Lin Du
study chair · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion